Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Voyager Therapeutics (VYGR) EBITDA Margin: 2015-2025

Historic EBITDA Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to -206.45%.

  • Voyager Therapeutics' EBITDA Margin fell 17171.00% to -206.45% in Q3 2025 from the same period last year, while for Sep 2025 it was -403.92%, marking a year-over-year decrease of 41985.00%. This contributed to the annual value of -81.70% for FY2024, which is 13470.00% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' EBITDA Margin is -206.45%, which was up 67.86% from -642.38% recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' EBITDA Margin registered a high of 1,516.65% during Q4 2022, and its lowest value of -3,252.89% during Q1 2022.
  • Over the past 3 years, Voyager Therapeutics' median EBITDA Margin value was -206.45% (recorded in 2025), while the average stood at -261.76%.
  • In the last 5 years, Voyager Therapeutics' EBITDA Margin plummeted by 292,005bps in 2022 and then soared by 333,538bps in 2023.
  • Over the past 5 years, Voyager Therapeutics' EBITDA Margin (Quarterly) stood at 20.30% in 2021, then soared by 149,634bps to 1,516.65% in 2022, then slumped by 145,380bps to 62.84% in 2023, then tumbled by 61,813bps to -555.29% in 2024, then plummeted by 17,171bps to -206.45% in 2025.
  • Its EBITDA Margin stands at -206.45% for Q3 2025, versus -642.38% for Q2 2025 and -474.05% for Q1 2025.